Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated CIK with bispecific antibody in advanced liver cancer
NCT03146637Phase 2Unknown
- Sponsor
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
- Start
- May 2017
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in liver cancer (2 arms), sponsored by Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Conditions
liver cancer
Beyond the preview
Go deeper on NCT03146637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146637.